The Current Role of Bevacizumab in the Treatment  of Hereditary Hemorrhagic Telangiectasia–Related Bleeding

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder with a worldwide prevalence rate of approximately 1 case per 5000 persons that results in vascular malformations throughout the body. At least 90% of patients are affected by nosebleeds and up to 81% have gastrointestinal telangiectasias.1 Both of these can result in severe bleeding and anemia that are refractory to conventional therapy (eg, iron infusions and endoscopic cautery of gastrointestinal and nasal telangiectasias) in perhaps as many as 10% to 15% of patients.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Editorial Source Type: research